Substitution of conventional cyclosporin with a new microemulsion formulation in renal transplant patients: Results after 1 year

Nephrology Dialysis Transplantation

Volumn 11, Issue 1, 1996, Pages 165-172

  Neumayer, H H ^a   Farber L ^c   Haller, P ^b   Kohnen, R ^d   Maibucher A ^c   Schuster, A ^c   Vollmar, J ^b   Budde, K ^a   Waiser, J ^a   Luft, F C ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Sandoz Corporation   (Germany)

^d Imerem Company   (Germany)

Author keywords

Cyclosporin as microemulsion; Nephrotoxicity; Rejection episodes; Renal transplantation

Indexed keywords

CREATININE; CYCLOSPORIN A; LIVER ENZYME; URIC ACID;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EMULSION; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; URIC ACID BLOOD LEVEL;

EID: 9044221764     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/11.1.165     Document Type: Article

References (25)

1. Lindholm A, Henricsson S, Lind M, Dahlqvist R Intraindividual variability in the relative systemic availability of cyclosporine after oral dosing. Eur J Clin Pharmacol 1988; 34: 461-464
2. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725-1738
3. Lemaire M, Fahr A, Maurer G. Pharmacokinetics of cyclosporine: inter- and intraindivdual variations and metabolic pathways Transplant Proc 1990; 22: 1110-1112
4. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993; 24: 472-495
5. Gupta SK, Manfro RC, Tomlanovich SJ, Gambertoglio JG, Garovoy MR, Bennet LZ. Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration, J Clin Pharmacol 1990; 30: 643-653
6. Korvarik JM, Mueller EA, van Bree JB et al. Cyclosporine pharmacokinetics and variability from a micro- emulsion formulation - a multicenter investigation in kidney transplant recipients. Transplantation 1994; 58: 658-663
7. Levy G, Rochon J, Freeman D et al. Cyclosporine Neoral in liver transplant recipients. Transplant Proc 1994; 26: 2949-2952
8. Trull AK, Tan KKC, Uttidge J, Bauer TT, Alexander GJM, Jamieson NV. Cyclosporine absorption from microemulsion formulation in liver transplant recipients. Lancet 1993; 344: 480-481
9. Ferrea G, Fioredda F, Loy A, Mangraviti S, Rossi G, Bassetti D. Oral microemulsion formulation substitutes for intravenous cyclosporine in child with graft versus-host disease. Lancet 1994; 344: 480-481
10. Lindholm A, Dahlqvist R, Groth GG, Sjöqvist F. A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation. Br J Clin Pharmacol 1990; 30: 443-452
11. Neumayer HH, Färber L, Haller P et al. Conversion from Sandimmun to Sandimmun Neoral in patients with stable renal allografts. Results after one month. Transplant Proc 1994; 85: 2944-2948
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
13. Keller F. Formula for urine-free determination of creatinine clearance in kidney transplant recipients. Z Transplantations medizin 1990; 4: 21-27
14. Welzel D, Kohnen R, Krüger HP, Drechsler S, Vollrath M, Seitz J. The Welzel Coloured Scales - A new method for meausuring subjective states and quality of life. Pharmacopsychiatry 1993; 26: 109
15. Burke JF, Pirsch JD, Ramos E et al. Long-term efficacy and safety of cyclosporine in renal transplant recipients. N Engl J Med 1994; 331: 358-363
16. Almond PS, Matas A, Gillingham K et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752-757
17. Wagner K, Philipp T, Heinemeyer G, Brockmüller J, Roots I, Neumayer HH. Interaction of cyclosporine-A and calcium antagonists Transplant Proc 1989; 21: 1453-1456
18. Kasiske BL, Heim-Duthow K, Rao KV Awni WM. The relationship between cyclosporine pharmacokinetics and rejection in renal transplant recipients. Transplantation 1988; 46: 716-722
19. Bach JF, Feutren G, Noel LH et al. Factors predictive of cyclosporine-induced nephrotoxicity: the role of cyclosporine blood levels. Transplant Proc 1990; 22: 1296-1298
20. Brockmöller J, Neumayer HH, Wagner K et al. Pharmacokinetic interaction between cyclosporine and diltiazem. Eur J Clin Pharmacol 1990; 38: 237-242
21. Kunzendorf U, Brockmöller J, Jochimsen F et al. Pharmakokinetik von Cyclosporin und seinen Metaboliten nach Nierentransplantation. Nieren- und Hochdruckkrankheiten 1990; 10: 500-504
22. Grevel J, Napoli KL, Kahan BD. Covariables in cyclosporine immunosuppression. Transplant Proc 1990; 22: 1113-1115
23. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosprine (part II). Clin Pharmacokinet 1990; 19: 400-415
24. Neumayer HH, Luft FC, and the Transplantationsgruppe Mittel- franken. Twenty-five years of renal transplantation from a single center: a risk factor analysis for short- and long-term outcomes. Clin Invest (Klin Wochenschr) 1993; 71: 341-350
25. Taesch S, Niese D. Safety and tolerability of a new oral formulation of cyclosporine A, Sandimmun Neoral, in renal transplant patients. Transplant Int 1994; 7: S263-S266